Imatinib (Glivec or Gleevec): Commemorative Topic in Honor of Dr Jürg Zimmermann on the Occasion of His 70th Anniversary

Topic Information

Dear Colleagues,

This Topic is dedicated to the 70th birthday of Jürg Zimmermann and to the enduring impact of his work on the evolution of targeted therapies in oncology. The development of Imatinib marked a turning point in modern pharmacology by demonstrating that rationally designed small molecules can precisely modulate disease-driving proteins with clinical efficacy. In this perspective, the Topic welcomes contributions that examine how structure-based drug design, kinase inhibition and molecular targeting have progressed over the last two decades, and how these foundations are enabling the next generation of therapeutics.

We invite submissions covering both established and emerging therapeutic strategies, including but not limited to the design, optimization and mechanism of action of selective inhibitors, allosteric modulators, covalent and reversible ligands, degraders, and agents that act through non-classical binding modes. Particular attention will be given to studies that explore mechanisms of resistance, signaling rewiring, pathway addiction, and compensatory survival networks in cancer and other diseases. In line with the disruptive nature of Imatinib at the time of its discovery, this Topic will also consider paradigm-breaking approaches and unconventional molecular architectures, such as macrocycles, supramolecular scaffolds, molecular glues, RNA-guided small molecules, spatially restricted therapeutics, immune-metabolic modulators and compounds targeting previously inaccessible or undruggable proteins.

Contributions bridging basic research and clinical translation are strongly encouraged, including biomarker validation, systems pharmacology analyses, patient-derived model studies, pharmacokinetic and pharmacodynamic investigations, or the integration of proteomics, metabolomics, lipidomics and other multi-omics approaches to dissect drug mechanisms and therapeutic response. Computational strategies, artificial intelligence-assisted screening and predictive modeling of ligand–target interactions and resistance evolution are also within the scope of this Topic. Submissions must present mechanistic insight, methodological rigor and clear implications for future therapeutic development inspired by the scientific legacy of Jürg Zimmermann.

Prof. Dr. Camillo Rosano
Prof. Dr. Xinyong Liu
Dr. Jessica Ceramella
Dr. Kateryna Tkachenko
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Molecules molecules	4.6	8.6	1996	16.1 Days	CHF 2700	Submit
International Journal of Molecular Sciences ijms	4.9	9.0	2000	20.5 Days	CHF 2900	Submit
Pharmaceutics pharmaceutics	5.5	10.0	2009	14.9 Days	CHF 2900	Submit
Pharmaceuticals pharmaceuticals	4.8	7.7	2004	14 Days	CHF 2900	Submit
Cancers cancers	4.4	8.8	2009	20.3 Days	CHF 2900	Submit
Chemistry chemistry	2.4	3.9	2019	18.5 Days	CHF 1800	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers